Abemaciclib plus endocrine therapy for hormone receptor- positive, HER2-negative, node-positive, high-risk, early breast cancer

被引：1
|
作者：
Nozawa, Kazuki [1 ]
Sawaki, Masataka [1 ]
Iwata, Hiroji [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 4648681, Japan
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 03期
关键词：
OPEN-LABEL;
D O I：
10.1016/S1470-2045(23)00014-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E103 / E103
页数：1
相关论文
共 50 条
  • [1] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
    Johnston, Stephen R. D.
    Toi, Masakazu
    O'Shaughnessy, Joyce
    Rastogi, Priya
    Campone, Mario
    Neven, Patrick
    Huang, Chiun-Sheng
    Huober, Jens
    Jaliffe, Georgina Garnica
    Cicin, Irfan
    Tolaney, Sara M.
    Goetz, Matthew P.
    Rugo, Hope S.
    Senkus, Elzbieta
    Testa, Laura
    Del Mastro, Lucia
    Shimizu, Chikako
    Wei, Ran
    Shahir, Ashwin
    Munoz, Maria
    San Antonio, Belen
    Andre, Valerie
    Harbeck, Nadia
    Martin, Miguel
    LANCET ONCOLOGY, 2023, 24 (01): : 77 - 90
  • [2] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
    D. Johnston, Stephen R.
    Rugo, Hope S.
    Tolaney, Sara M.
    Fernandez, Maria Munoz
    Wei, Ran
    Martin, Miguel
    FUTURE ONCOLOGY, 2024, 20 (28) : 2037 - 2048
  • [3] Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Giovany Orozco Leal
    Nigel Armstrong
    Ashleigh Kernohan
    Charlotte Ahmadu
    Diarmuid Coughlan
    Kevin McDermott
    Steven Duffy
    Susan O’Meara
    Tomos Robinson
    Luke Vale
    Jos Kleijnen
    PharmacoEconomics, 2023, 41 : 741 - 750
  • [4] Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Orozco Leal, Giovany
    Armstrong, Nigel
    Kernohan, Ashleigh
    Ahmadu, Charlotte
    Coughlan, Diarmuid
    McDermott, Kevin
    Duffy, Steven
    O'Meara, Susan
    Robinson, Tomos
    Vale, Luke
    Kleijnen, Jos
    PHARMACOECONOMICS, 2023, 41 (07) : 741 - 750
  • [5] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [6] Real-world Data on Safety Outcome with Treatment of Adjuvant Abemaciclib plus Endocrine Therapy in High-risk Early Hormone-positive, HER2-negative Breast Cancer Patients
    Neralla, H.
    Herring, K.
    Stevens, A.
    Rea, D.
    Pallan, L.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E110 - E111
  • [7] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
    Tolaney, Sara M.
    Fallowfield, Lesley
    Kaufman, Peter A.
    Ciruelos, Eva M.
    Gainford, Mary Corona
    Lu, Yi
    Hurt, Karla
    Wasserstrom, Heather Ann
    Chen, Yanyun
    Goel, Shom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer
    Pusztai, Lajos
    Hoag, Jess R.
    Albain, Kathy S.
    Barlow, William E.
    Stemmer, Salomon M.
    Meisner, Allison
    Hortobagyi, Gabriel N.
    Shak, Steven
    Hayes, Daniel F.
    Rae, James M.
    Baehner, Frederick
    Sharma, Priyanka
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review
    Garutti, Mattia
    Griguolo, Gaia
    Botticelli, Andrea
    Buzzatti, Giulia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Molinelli, Chiara
    Adamo, Vincenzo
    Bianchini, Giampaolo
    Biganzoli, Laura
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    Fabi, Alessandra
    Frassoldati, Antonio
    Gennari, Alessandra
    Marchio, Caterina
    Perrone, Francesco
    Viale, Giuseppe
    Zamagni, Claudio
    Zambelli, Alberto
    Del Mastro, Lucia
    De Placido, Sabino
    Guarneri, Valentina
    Marchetti, Paolo
    Puglisi, Fabio
    CANCERS, 2022, 14 (08)
  • [10] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast Cancer
    Friedman-Eldar, Orli
    Ozmen, Tolga
    Reyes, Fernando Valle
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susane B.
    Moller, Mecker
    Franceschi, Dido
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236
12345